Cinctive Capital Management LP Buys 71,164 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Cinctive Capital Management LP grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 43.8% during the third quarter, HoldingsChannel reports. The firm owned 233,495 shares of the company’s stock after purchasing an additional 71,164 shares during the quarter. Cinctive Capital Management LP’s holdings in Teva Pharmaceutical Industries were worth $4,208,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of TEVA. Vanguard Group Inc. grew its stake in Teva Pharmaceutical Industries by 3.5% in the first quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock worth $11,648,000 after purchasing an additional 28,071 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Teva Pharmaceutical Industries by 21.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 201,849 shares of the company’s stock worth $2,849,000 after buying an additional 36,295 shares during the period. DekaBank Deutsche Girozentrale increased its stake in shares of Teva Pharmaceutical Industries by 6.1% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 72,127 shares of the company’s stock worth $1,036,000 after acquiring an additional 4,131 shares in the last quarter. GAMMA Investing LLC lifted its position in Teva Pharmaceutical Industries by 105.7% during the 2nd quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after acquiring an additional 1,741 shares during the period. Finally, DNB Asset Management AS boosted its stake in Teva Pharmaceutical Industries by 9.6% during the second quarter. DNB Asset Management AS now owns 160,302 shares of the company’s stock worth $2,605,000 after acquiring an additional 14,001 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.55% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays raised their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Stock Down 0.8 %

Shares of TEVA opened at $16.65 on Tuesday. The firm has a fifty day simple moving average of $17.54 and a two-hundred day simple moving average of $17.36. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 1-year low of $9.35 and a 1-year high of $19.31.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.